NCT04831944View on ClinicalTrials.gov

To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment.

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

March 29, 2021

Primary Completion Date

March 10, 2022

Study Completion Date

March 11, 2022

Conditions
Advanced Malignancies
Interventions
DRUG

parsaclisib

parsaclisib will be administered orally after 8 hours of fasting.

Trial Locations (5)

32809

Orlando Clinical Research Center, Orlando

33014

Clinical Pharmacology of Miami, Hialeah

78215

Texas Liver Institute Tli the Liver Institute of South Texas List Downtown Office, San Antonio

92377

Inland Empire Liver Foundation, Rialto

92780

Orange County Research Center, Tustin

Sponsors

Lead Sponsor

Incyte Corporation
All Listed Sponsors
lead

Incyte Corporation

INDUSTRY

NCT04831944 - To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment. | Biotech Hunter | Biotech Hunter